BioNexus Gene Lab

BioNexus Gene Lab EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioNexus Gene Lab (BGLC) as of Oct 29, 2026 is -3.16 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -1.57 M USD — a change of 100.70% (lower).

EBITDA

-3.16 MUSD

YoY

100.70%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioNexus Gene Lab is 2025 -3.16 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioNexus Gene Lab was 2024 -1.57 M USD. It decreases by 100.70% lower compared to the previous year.

The BioNexus Gene Lab EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
59,901.00 USD
Jan 1, 2019
-275,705.00 USD
Jan 1, 2020
1.27 M USD
Jan 1, 2021
1.06 M USD
Jan 1, 2022
-291,177.00 USD
Jan 1, 2023
-2.59 M USD
Jan 1, 2024
-1.57 M USD
Jan 1, 2025
-3.16 M USD
The BioNexus Gene Lab EBITDA history
YEAREBITDAYoY
-3.16 MUSD+100.70%
-1.57 MUSD-39.31%
-2.59 MUSD+790.53%
-291,177.00USD-127.58%
1.06 MUSD-17.11%
1.27 MUSD-562.02%
-275,705.00USD-560.27%
59,901.00USD-146.83%
-127,910.00USD+15,127.38%
-840.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BioNexus Gene Lab Stock analysis

What does BioNexus Gene Lab do? BioNexus Gene Lab Corp. develops and markets non-invasive blood tests for early disease detection, analyzing RNA changes to assess risks for over 11 diseases. The company’s subsidiary, Bionexus Gene Lab Sdn. Bdh., supports these operations. Products are sold to healthcare providers and diagnostic centers seeking advanced, non-invasive testing solutions. The firm targets medical professionals and institutions focused on personalized health management through functional genomics applications. The company generates revenue through the sale of its RNA-based blood tests, which are marketed as tools for early disease risk assessment. Healthcare institutions and diagnostic service providers purchase these tests to enhance their diagnostic capabilities. The focus on non-invasive methods aligns with growing demand for patient-friendly diagnostic technologies in the molecular diagnostics sector. BioNexus Gene Lab Corp. operates with a small team of 5 full-time employees, emphasizing efficiency in product development and marketing. The subsidiary Bionexus Gene Lab Sdn. Bdh. facilitates local operations, though specific market segments are not detailed beyond healthcare providers and diagnostic centers. Revenue streams are derived solely from test sales, with no mention of additional services or partnerships. BioNexus Gene Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioNexus Gene Lab stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioNexus Gene Lab is -3.16 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioNexus Gene Lab changed from -1.57 M USD to -3.16 M USD, representing a 100.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) BioNexus Gene Lab since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s BioNexus Gene Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — BioNexus Gene Lab

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — BioNexus Gene Lab